EBR Systems (EBR) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
21 Jan, 2026Opening remarks and agenda
Special Meeting scheduled for 12 March 2026 at 0900 AEDT, to be held virtually, with notice posted online around January 28, 2026.
Meeting convened to clarify the special meeting, address shareholder confusion about share consolidation, and provide voting and participation details.
Specific resolutions to be voted on
Proposal to approve a reverse consolidation of common shares within a 5-to-1 to 20-to-1 range, with the exact ratio to be determined by the board.
ASX shares (CDIs) will not be consolidated; only common shares are affected, with the CDI-to-common share ratio adjusted proportionally.
Shareholder approval required to enact the consolidation and free up authorized shares for future activities.
Shareholder proposals specific to EGM
Share consolidation is the main agenda item, intended to increase available authorized shares for future financings, acquisitions, or strategic opportunities.
Latest events from EBR Systems
- FDA approval and U.S. launch drove $1.6M revenue but net loss reached $48.8M in 2025.EBR
Q4 202520 Mar 2026 - Shareholders voted on a reverse stock split and ratification of a prior securities issuance.EBR
EGM 202611 Mar 2026 - Only FDA-approved, fully leadless CRT device, targeting a $5.8bn US market with rapid growth.EBR
Investor presentation9 Mar 2026 - Leadless left ventricular pacing launches with FDA approval, strong adoption, and $5.8B TAM.EBR
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - FDA approval, funding, and commercialization plans defined a pivotal year; key proposals were voted.EBR
AGM 202525 Nov 2025 - Q3 2025 revenue surged 201% sequentially, but net loss increased to $12.2 million.EBR
Q3 2025 TU23 Nov 2025 - FDA approval and first U.S. sales of WiSE CRT System mark a pivotal commercialization milestone.EBR
Q2 2025 TU7 Sep 2025 - Leadless CRT device with pivotal trial success targets US$3.6bn market and FDA approval in 2025.EBR
Investor Presentation30 Jun 2025 - Only leadless CRT device with FDA approval expected by April 2025 and $3.6bn market opportunity.EBR
Investor Presentation30 Jun 2025